N/A
N=480
Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy · Sedentary Lifestyle · Hypoglycemia
Bottom Line
View on ClinicalTrials.gov: NCT01409382 ↗Enrolled (actual)
480
Serious AEs
23.8%
Results posted
Jan 2016
Primary outcome: Primary: Neonatal Hypoglycemia — 3; 15 neonates
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Daily brisk walking plus a carbohydrate-restricted diet (Behavioral)
- Age
- Pediatric, Adult
- Sex
- All
- Sponsor
- Hospital dos Servidores do Estado do Rio de Janeiro
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neonatal Hypoglycemia |
3; 15 | — |
| SECONDARY Refractory Hypoglycemia |
0; 3 | — |
Summary
tPA has a pivotal role in placentation, mediationg activation of growth factors, such as vascular endothelial growth factor and brain-derived neurotrophic factor, degradation of extracellular matrix and basement membrane (directly or through activation of matrix metalloproteinases) and formation of hemidesmosomes.
A high-carbohydrate intake combined with lack of physical activity provides a strong stimulus for maternal insulin production. In this scenario, either β-cells are dysfunctional and diabetes supervenes, or excessive amounts of insulin are produced, providing pathological stimulation of PAI-1 synthesis. Given that PAI-1 is a major tPA inhibitor, PAI-1 excess may affect placentation, increasing the risk of first trimester losses, preterm deliveries and intrauterine growth restriction.
Our hypothesis was that prematurity was not the cause of neonatal hypoglycemia, but a parallel occurrence of a strong stimulus for maternal, fetal and neonatal production of insulin.
Eligibility Criteria
Inclusion criteria: recurrent early unexplained miscarriages Exclusion criteria: (i) antiphospholipid antibodies, (ii) second- or third-trimester losses, (iii) multiple pregnancy, (iv) anatomical abnormalities that could increase the risk of early miscarriages, (iv) any condition requiring a priori anticoagulation, (v) protocol violation.
Data sourced from ClinicalTrials.gov (NCT01409382). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.